News und Analysen

What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how

Buying low to sell later when the stock's price is high is a time-honored investing strategy. With the benchmark S&P 500 index near its all-time high, though, now might seem like the wrong time to

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the

Masimo (NASDAQ:MASI), a provider of noninvasive patient monitoring technology, released its fourth-quarter earnings for 2024, on Feb. 25, 2025. The results presented a mixed picture: strong

A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock. However, the company paying that dividend needs to be healthy to ensure

Medical device manufacturer Medtronic (NYSE: MDT) is a healthcare industry stalwart. The company, based in the U.S. and Ireland, is one of the largest in its segment, developing and selling a

The U.S. Department of Justice has reportedly launched an investigation into UnitedHealth Group's (NYSE: UNH) Medicare billing practices.

Investors were shaken by the report, sending UnitedHealth

In this episode of the Motley Fool Scoreboard, analysts evaluate Trupanion (NASDAQ: TRUP) and its potential as a pet insurance leader. With a solid track record and a growing market, is Trupanion a

Trupanion (NASDAQ:TRUP), a leader in pet medical insurance, released its Q4 2024 earnings on February 19, 2025. The company delivered mixed results, with earnings per share (EPS) at $0.04, missing

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q3 2025 Earnings CallFeb 18, 2025, 8:00 a.m. ET

Ryan Weispfenning -- Vice President and Head, Investor Relations

Continue reading

Source Fool.com

It's a reasonable concern for Rivian Automotive (NASDAQ: RIVN) investors that the company has no real visible catalysts in 2025. The R2 won't launch until 2026, Rivian already inked a big deal with

Image source: The Motley Fool.

DexCom (NASDAQ: DXCM)Q4 2024 Earnings CallFeb 13, 2025, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue

Healthcare in vitro diagnostics company QuidelOrtho (NASDAQ: QDEL) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather

I'm about to get a big cash infusion in my portfolio. Last year, private equity giant Blackstone agreed to buy one of my holdings, Retail Opportunity Investments Corp., in an all-cash deal. That

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time, the S&P